Announced Sat, 10 May · 14:46 IST

Submission of outcome of EGM held on 09th May, 2025.

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Novelix Pharmaceuticals (BSE: 536565, script id NOVELIX) held an Extra Ordinary General Meeting on 9 May 2025 via video conferencing from 3:35 PM to 3:58 PM, attended by 26 members. Two items of business were transacted: (1) a Special Resolution to confirm the appointment of Mr. Lakshman Samala (DIN: 10783725) as an Independent Director, and (2) an Ordinary Resolution to confirm the appointment of Mr. Jivamohan Divakar Valluri (DIN: 09218013) as a Non-Executive Non-Independent Director. Remote e-voting was conducted from 6 May to 8 May 2025, with CDSL as the e-voting facilitator and Mr. Ankur Khedar (Practicing CA) as the Scrutinizer. The combined voting results (remote e-voting plus e-voting at the meeting) are yet to be announced and will be disclosed to the stock exchange within 48 hours.

Likely market impact

Voting outcomes on the two director appointments are still pending and will be released shortly, which will finalise the board composition. No immediate material business or financial impact for shareholders; this is a routine governance filing.